Physician profile
Tarrah L Holliday
NPI 1114521721
$420,793.98
in general payments reported to CMS, 2019-2025
13 companies · $151K in 2025
The $151K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $710 · 2022: $24K · 2023: $122K · 2024: $123K · 2025: $151K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $297K · Travel and Lodging: $64K · Consulting Fee: $19K · Food and Beverage: $16K · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $296,940.00 |
| Travel and Lodging | $64,379.86 |
| Consulting Fee | $18,779.98 |
| Food and Beverage | $15,505.97 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $419,514.84 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $309.20 | 2021-2025 | Uzedy |
| Abbvie INC. | $201.61 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $176.86 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.01 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $118.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $109.57 | 2021-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $56.41 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $54.67 | 2025 | Rexulti |
| Corium, LLC | $46.22 | 2025 | Azstarys |
| Indivior INC. | $18.50 | 2023 | Perseris |
| Jazz Pharmaceuticals INC. | $15.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.05 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarrah Holliday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.